{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:25:44Z","timestamp":1788323144223,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.blre.2026.101393","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:13:22Z","timestamp":1777011202000},"page":"101393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): A practical compartment-based review"],"prefix":"10.1016","volume":"77","author":[{"given":"Pablo","family":"Mozas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Combalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Antelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"L\u00f3pez-Oreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Castrej\u00f3n de Anta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Monge-Escart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Moreno-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gil-Lianes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"Juncosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Queralt","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Charry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Albero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Garc\u00eda-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Estrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101393_bb0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0010","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ajh.27735","article-title":"Mycosis fungoides, s\u00e9zary syndrome, and cutaneous B-cell lymphomas: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Hristov","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101393_bb0015","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and s\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101393_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-024-01002-0","article-title":"Dual t-cell constant \u03b2 chain (TRBC)1 and TRBC2 staining for the identification of t-cell neoplasms by flow cytometry","volume":"14","author":"Horna","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101393_bb0030","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood.2021012286","article-title":"Improved s\u00e9zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in s\u00e9zary syndrome","volume":"138","author":"Najidh","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101393_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (t2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaad.2016.03.009","article-title":"New insights into folliculotropic mycosis fungoides (FMF): a single-center experience","volume":"75","author":"Hodak","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0050","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","article-title":"Clinical staging and prognostic factors in folliculotropic mycosis fungoides","volume":"152","author":"van Santen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102679","article-title":"Real-life efficacy of immunotherapy for s\u00e9zary syndrome: a multicenter observational cohort study","volume":"73","author":"Bozonnat","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.blre.2026.101393_bb0060","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and s\u00e9zary syndrome","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2026.101393_bb0065","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in s\u00e9zary syndrome and mycosis fungoides","volume":"148","author":"Cetin\u00f6zman","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0070","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.3390\/ijms26125500","article-title":"Structural insights into the ADCC mechanism and resistance of mogamulizumab, a first-in-class anti-CCR4 therapy for cutaneous t cell lymphoma","volume":"26","author":"Choi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101393_bb0075","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous t-cell lymphoma","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0080","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3390\/cancers16193368","article-title":"The tumor microenvironment as a therapeutic target in cutaneous t cell lymphoma","volume":"16","author":"Kwantwi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101393_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291259","article-title":"Advancements in the treatment of mycosis fungoides and s\u00e9zary syndrome: monoclonal antibodies, immunotherapies, and janus kinase inhibitors","volume":"14","author":"Quadri","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101393_bb0090","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant t-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0095","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1007\/s10238-023-01141-x","article-title":"An update on mechanisms of pruritus and their potential treatment in primary cutaneous t-cell lymphoma","volume":"23","author":"Hu","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2026.101393_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1043254","article-title":"Advances in the understanding and treatment of cutaneous t-cell lymphoma","volume":"12","author":"Bakr","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0105","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in t-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/1750743X.2025.2520153","article-title":"Evaluating mogamulizumab in the treatment of primary cutaneous t-cell lymphoma","volume":"17","author":"Oymanns","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.blre.2026.101393_bb0115","series-title":"Extracorporeal Photopheresis-An Overview Front Med (Lausanne)","first-page":"236","volume":"5","author":"Cho","year":"2018"},{"key":"10.1016\/j.blre.2026.101393_bb0120","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.3390\/cancers13215512","article-title":"Targeted deep sequencing of mycosis fungoides reveals intracellular signaling pathways associated with aggressiveness and large cell transformation","volume":"13","author":"Wobser","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101393_bb0125","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0130","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2014.11.015","article-title":"S\u00e9zary syndrome without erythroderma","volume":"72","author":"Henn","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0140","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0145","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.2025029628","article-title":"A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification","volume":"146","author":"Scarisbrick","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0150","series-title":"NCCN clinical practice guidelines in oncology: Primary cutaneous lymphomas","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"10.1016\/j.blre.2026.101393_bb0155","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jtct.2024.08.020","article-title":"ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and s\u00e9zary syndrome","volume":"30","author":"Goyal","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2026.101393_bb0160","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/s41409-025-02696-x","article-title":"Allogeneic hematopoietic cell transplant in cutaneous t-cell lymphomas: recommendations from the EBMT PH&G committee","volume":"60","author":"Damaj","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101393_bb0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and s\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0170","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101393_bb0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaad.2020.05.043","article-title":"Response to topical corticosteroid monotherapy in mycosis fungoides","volume":"84","author":"Kartan","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115064","article-title":"Radiotherapy in cutaneous lymphomas: recommendations from the EORTC cutaneous lymphoma tumour group","volume":"212","author":"Elsayad","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101393_bb0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.blre.2026.101393_bb0195","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous t-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0200","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2012.07.013","article-title":"Acitretin for the treatment of cutaneous t-cell lymphoma","volume":"68","author":"Cheeley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0210","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1002\/cam4.4237","article-title":"Alitretinoin in the treatment of cutaneous t-cell lymphoma","volume":"10","author":"Kaemmerer","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101393_bb0215","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/jdv.20350","article-title":"Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: real-world data from a multicentre study","volume":"39","author":"Nikolaou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.blre.2026.101393_bb0220","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.20225","article-title":"Large-cell transformation of mycosis fungoides: patterns of care and patient outcomes","volume":"207","author":"Johnstone","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101393_bb0225","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.prro.2025.06.006","article-title":"Modified recommendations for the radiation dose in patients with mycosis fungoides and localized lesional disease based on a retrospective analysis of treatment outcomes","volume":"15","author":"Kersten","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1498855","article-title":"Total skin electron beam therapy","volume":"15","author":"Specht","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0235","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.rpor.2013.07.006","article-title":"First treatment of mycosis fungoides by total skin electron beam (TSEB) therapy in Greece","volume":"19","author":"Diamantopoulos","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.blre.2026.101393_bb0240","first-page":"1534","article-title":"Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and s\u00e9zary syndrome: results from the prospective S-MISR study","volume":"23","author":"Elsayad","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.blre.2026.101393_bb0245","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00065","article-title":"Low-dose total skin electron beam radiotherapy in stage IB-IIB mycosis fungoides: results from the prospective S-MISR study","author":"Elsayad","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.blre.2026.101393_bb0250","first-page":"279","article-title":"Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous t-cell lymphoma","volume":"20","author":"Elsayad","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.blre.2026.101393_bb0255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.transci.2011.10.016","article-title":"The role of extracorporeal photopheresis in the treatment of cutaneous t-cell lymphomas","volume":"46","author":"Atta","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2026.101393_bb0260","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.det.2015.05.011","article-title":"Extracorporeal photopheresis in the treatment of mycosis fungoides and s\u00e9zary syndrome","volume":"33","author":"Zic","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.blre.2026.101393_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2312250","article-title":"Outcomes of extracorporeal photopheresis in a diverse cohort of patients with cutaneous t-cell lymphoma: a retrospective study at a tertiary care hospital","volume":"35","author":"Weiner","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.blre.2026.101393_bb0270","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1111\/jdv.13243","article-title":"Erythrodermic mycosis fungoides and s\u00e9zary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: a single-Centre experience","volume":"29","author":"Atzmony","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.blre.2026.101393_bb0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/hematology.2021000263","article-title":"What factors guide treatment selection in mycosis fungoides and sezary syndrome?","volume":"2021","author":"Kim","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2026.101393_bb0280","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous t-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-021-00624-7","article-title":"Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: characterization and management","volume":"12","author":"Musiek","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.blre.2026.101393_bb0290","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of mogamulizumab-associated rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2026.101393_bb0295","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicians choice in cutaneous t-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101393_bb0300","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/bjd\/ljaf521","article-title":"Radioimmunotherapy combined with antibody\u2013drug conjugate-induced radiosensitization leads to long-term remission of mycosis fungoides","volume":"194","author":"Oymanns","year":"2026","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/14737140.5.1.39","article-title":"Alemtuzumab","volume":"5","author":"Ravandi","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2026.101393_bb0310","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","article-title":"Alemtuzumab therapy for leukemic cutaneous t-cell lymphoma: diffuse erythema as a positive predictor of complete remission","volume":"150","author":"Watanabe","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0315","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428199809057618","article-title":"Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP","volume":"31","author":"Fierro","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101393_bb0320","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0325","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.blre.2026.101393_bb0330","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous t-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101393_bb0335","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and s\u00e9zary syndrome. An updated experience of the lymphoma working party of the european society for blood and marrow transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101393_bb0340","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous t-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2026.101393_bb0345","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO-25-00183","article-title":"Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score\u2013Matched Controlled Prospective Study","volume":"43","author":"de Masson","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0350","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0355","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell Leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101393_bb0360","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous t-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101393_bb0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/14737140.2024.2305356","article-title":"Allogeneic transplantation and cellular therapies in cutaneous t-cell lymphoma","volume":"24","author":"Goyal","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.blre.2026.101393_bb0370","first-page":"2212","article-title":"Transformation of mycosis fungoides: Clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas","volume":"vol. 95","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101393_bb0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cup.13375","article-title":"Utility of CD30, ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation","volume":"46","author":"Raghavan","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.blre.2026.101393_bb0380","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2018.02.011","article-title":"Pruritus in cutaneous T-cell lymphoma and its management","volume":"36","author":"Serrano","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.blre.2026.101393_bb0385","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:11:54Z","timestamp":1787951514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":77,"alternative-id":["S0268960X26000329"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101393","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): A practical compartment-based review","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101393"}}